The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

Trial Profile

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs LEO 27847 (Primary)
  • Indications Hyperparathyroidism; Kidney disorders
  • Focus Pharmacokinetics
  • Sponsors LEO Pharma
  • Most Recent Events

    • 05 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top